Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Purpose: Because of atypical response imaging patterns in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs), new biomarkers are needed for a better monitoring of treatment efficacy. The aim of this prospective study was to evaluate the prognostic value of volume-derived positron-emission tomography (PET) parameters on baseline and follow-up 18 F-fluoro-deoxy-glucose PET ( 18 F-FDG-PET) scans and compare it with the conventional PET Response Criteria in Solid Tumors (PERCIST). Methods: Patients with metastatic NSCLC were included in two different single-center prospective trials. 18 F-FDG-PET studies were performed before the start of immunotherapy (PET baseline ), after 6–8 weeks (PET interim 1) and after 12–16 weeks (PET interim 2) of treatment, using PERCIST criteria for tumor response assessment. Different metabolic parameters were evaluated: absolute values of maximum standardized uptake value (SUVmax) of the most intense lesion, total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), but also their percentage changes between PET studies (ΔSUVmax, ΔTMTV and ΔTLG). The median follow-up of patients was 31 (7.3–31.8) months. Prognostic values and optimal thresholds of PET parameters were estimated by ROC (Receiver Operating Characteristic) curve analysis of 12-month overall survival (12M-OS) and 6-month progression-free survival (6M-PFS). Tumor progression needed to be confirmed by a multidisciplinary tumor board, considering atypical response patterns on imaging. Results: 110 patients were prospectively included. On PET baseline , TMTV was predictive of 12M-OS [AUC (Area Under Curve) =0.64; 95% CI: 0.61 to 0.66] whereas SUVmax and TLG were not. On PET interim 1 and PET interim 2, all metabolic parameters were predictive for 12M-OS and 6M-PFS, the residual TMTV on PET interim 1 (TMTV 1 ) being the strongest prognostic biomarker (AUC=0.83 and 0.82; 95% CI: 0.74 to 0.91, for 12M-OS and 6M-PFS, respectively). Using the optimal threshold by ROC curve to classify patients into three TMTV 1 subgroups (0 cm 3 ; 0–57 cm 3 ; >57 cm 3 ), TMTV 1 prognostic stratification was independent of PERCIST criteria on both PFS and OS, and significantly outperformed them. Subgroup analysis demonstrated that TMTV 1 remained a strong prognostic biomarker of 12M-OS for non-responding patients (p=0.0003) according to PERCIST criteria. In the specific group of patients with PERCIST progression on PET interim 1, low residual tumor volume (<57 cm 3 ) was still associated with a very favorable patients’ outcome (6M-PFS=73%; 24M-OS=55%). Conclusion: The absolute value of residual metabolic tumor volume, assessed 6–8 weeks after the start of ICPI, is an optimal and independent prognostic measure, exceeding and complementing conventional PERCIST criteria. Oncologists should consider it in patients with first tumor progression according to PERCIST criteria, as it helps identify patients who benefit from continued treatment. Trial registration number: 2018-A02116-49; NCT03584334 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Nioche, C., Orlhac, F., Boughdad, S., Reuzé, S., Goya-Outi, J., Robert, C., Pellot-Barakat, C., Soussan, M., Frouin, F., & Buvat, I. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0125 · Cited by 1,167
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Horn, L., Spigel, D. R., Vokes, E. E., Holgado, E., Ready, N., Steins, M., Poddubskaya, E., Borghaei, H., Felip, E., Paz-Ares, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3062 · Cited by 861
(2004) · PubMed · Cited by 653
Tumour burden and efficacy of immune-checkpoint inhibitors
Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00564-3 · Cited by 350 · cited 1×
“While the median delay between a baseline PET scan and the initiation of ICPI was 7 days, nearly one in six patients had a baseline PET study more than 1-month prior to the start of treatment, despite the expectation that Open access PET findings would evolve over the course of a month for NSCLC.”
BackgroundTazdait, M., Mezquita, L., Lahmar, J., Ferrara, R., Bidault, F., Ammari, S., Balleyguier, C., Planchard, D., Gazzah, A., Soria, J. C., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.017 · Cited by 349 · cited 1×
“16 Therefore, PERCIST criteria underestimate the efficacy of ICPIs, and new PET imaging criteria are needed to better distinguish between patients who benefit from ICPI and those who do not.”
BackgroundNoninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.001 · Cited by 347
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Lantuejoul, S., Sound-Tsao, M., Cooper, W. A., Girard, N., Hirsch, F. R., Roden, A. C., Lopez-Rios, F., Jain, D., Chou, T.-Y., Motoi, N., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.107 · Cited by 332
Guibert, N., Delaunay, M., Lusque, A., Boubekeur, N., Rouquette, I., Clermont, E., Mourlanette, J., Gouin, S., Dormoy, I., Favre, G., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.001 · Cited by 236
Blanc‐Durand, P., Jégou, S., Kanoun, S., Berriolo-Riedinger, A., Bodet‐Milin, C., Kraeber‐Bodéré, F., Carlier, T., Gouill, S. L., Casasnovas, O., Meignan, M. A., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05080-7 · Cited by 165
Capobianco, N., Meignan, M. A., Cottereau, A., Vercellino, L., Sibille, L., Spottiswoode, B. S., Zuehlsdorff, S., Casasnovas, O., Thiéblemont, C., & Buvat, I. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.242412 · Cited by 155
Lopci, E., Hicks, R. J., Dimitrakopoulou‐Strauss, A., Dercle, L., Iravani, A., Seban, R., Sachpekidis, C., Humbert, O., Gheysens, O. S., Glaudemans, A. W. J. M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05780-2 · Cited by 128
Self-citationSeban, R., Mezquita, L., Berenbaum, A., Dercle, L., Botticella, A., Péchoux, C. L., Caramella, C., Deutsch, E., Grimaldi, S., Adam, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04615-x · Cited by 126
Humbert, O., Cadour, N., Paquet, M., Schiappa, R., Poudenx, M., Chardin, D., Borchiellini, D., Benisvy, D., Ouvrier, M. J., Zwarthoed, C., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04573-4 · Cited by 99
Self-citationCastello, A., Rossi, S., Mazziotti, E., Toschi, L., & Lopci, E. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.237768 · Cited by 90
Chardin, D., Paquet, M., Schiappa, R., Darcourt, J., Bailleux, C., Poudenx, M., Sciazza, A., Ilié, M., Benzaquen, J., Martin, N., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000645 · Cited by 90 · cited 1×
“33–36”
Self-citationEvangelista, L., Cuppari, L., Menis, J., Bonanno, L., Reccia, P., Frega, S., & Pasello, G. (2019) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001025 · Cited by 79 · cited 1×
“17 18 The aim of this study was to prospectively investigate the prognostic value of 18 F-FDG PET metabolic parameters during the first 3 months of ICPIs treatment in patients with metastatic NSCLC, focusing on metabolic parameters derived from tumor volume.”
BackgroundDriessen, J., Zwezerijnen, G. J. C., Schöder, H. M., Drees, E. E. E., Kersten, M. J., Moskowitz, A. J., Moskowitz, C. H., Eertink, J. J., de Vet, H. C. W., Hoekstra, O. S., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263067 · Cited by 70
Hashimoto, K., Kaira, K., Yamaguchi, O., Mouri, A., Shiono, A., Miura, Y., Murayama, Y., Kobayashi, K., Kagamu, H., & Kuji, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030725 · Cited by 58
Im, H., Kim, Y. K., Kim, Y.-I., Lee, J. J., Lee, W. W., & Kim, S. E. (2012) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-012-0181-5 · Cited by 49
Onesti, C. E., Frères, P., & Jérusalem, G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.47 · Cited by 46 · cited 1×
“14 Consequently, when using ICPI, new response patterns have been described such as a transient tumor increase in size and metabolism, or the appearance of new lesions, followed by a delayed response or stability.”
MethodCastello, A., Carbone, F. G., Rossi, S., Monterisi, S., Federico, D., Toschi, L., & Lopci, E. (2020) · Cancers · doi:10.3390/cancers12020487 · Cited by 45 · cited 1×
“33–36”
Jiang, C., Chen, K., Teng, Y., Ding, C., Zhou, Z., Gao, Y., Wu, J., He, J., He, K., & Zhang, J. (2022) · European Radiology · doi:10.1007/s00330-022-08573-1 · Cited by 45
Monaco, L., Gemelli, M. T., Gotuzzo, I., Bauckneht, M., Crivellaro, C., Genova, C., Cortinovis, D. L., Zullo, L., Ammoni, L. C., Bernasconi, D. P., et al. (2021) · Cancers · doi:10.3390/cancers13071634 · Cited by 39 · cited 2×
“Lastly, the manual segmentation of tumorous lesions, required for MTV measurement, is currently a limitation for its adoption in routine practice: it is time-consuming (around 15 min per study) and tedious.”
BackgroundAwada, G., Jansen, Y. J. L., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S. E., Schats, K., van Dam, P., et al. (2021) · Cancers · doi:10.3390/cancers13020168 · Cited by 38
Lang, D., Ritzberger, L., Rambousek, V., Horner, A., Wass, R. E., Akbari, K., Kaiser, B., Kronbichler, J., Lamprecht, B., & Gabriel, M. (2021) · Cancers · doi:10.3390/cancers13236096 · Cited by 21 · cited 1×
“While the median delay between a baseline PET scan and the initiation of ICPI was 7 days, nearly one in six patients had a baseline PET study more than 1-month prior to the start of treatment, despite the expectation that Open access PET findings would evolve over the course of a month for NSCLC.”
BackgroundTibdewal, A. R., Patil, M., Misra, S., Purandare, N. C., Rangarajan, V., Mummudi, N. B., Karimundackal, G., Jiwnani, S. S., & Agarwal, J. (2021) · Indian Journal of Nuclear Medicine · doi:10.4103/ijnm.ijnm_134_20 · Cited by 13 · cited 1×
“33–36”
Dirks, I., Keyaerts, M., Dirven, I., Neyns, B., & Vandemeulebroucke, J. (2023) · Cancers · doi:10.3390/cancers15164083 · Cited by 12
Bianchi, A., Rimini, M. L. D., Sciuto, R., Annovazzi, A., Traglia, S. D., Bauckneht, M., Lanfranchi, F., Morbelli, S. D., Nappi, A. G., Ferrari, C., et al. (2023) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2022.0092 · Cited by 3
Research works printed but not linked: 6
- 20. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143-52. · DOI · Paper page
- 23. Nabet BY, Esfahani MS, Moding EJ, et al. Noninvasive early identification of therapeutic benefit from immune Checkpoint inhibition. Cell 2020;183:363-76. · DOI · Paper page
- 27. Im H-J, Kim YK, Kim Y-I, et al. Usefulness of combined metabolic- volumetric indices of 18F-FDG PET/CT for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer. Nucl Med Mol Imaging 2013;47:36-43. · DOI
- 29. Driessen J, Zwezerijnen GJC, Schöder H, et al. The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in 18 F -FDG PET scans of patients with classical Hodgkin lymphoma. J Nucl Med 2022;63:1424-30. · DOI
- 32. Capobianco N, Meignan M, Cottereau A-S, et al. Deep-learning 18F-FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma. J Nucl Med 2021;62:30-6. · DOI
- 36. 18 F]FDG PET/CT imaging and clinical features. Cancers (Basel) 2023;15:4083. on April 22, 2024 by guest. Protected by copyright. http://jitc.bmj.com/ J Immunother Cancer: first published as 10.1136/jitc-2023-007628 on 22 April 2024. Downloaded from
Cited by
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 122
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
Zheng, J., Xu, S., Wang, G., & Shi, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1434171 · Cited by 28
Huang, M., Zou, Y., Wang, W., Li, Q., & Tian, R. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241293364 · Cited by 23
“20,21 The prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) is frequently reported in many cancers, 22–25 as well as in NSCLC patients undergoing surgery, chemotherapy, or radiotherapy.”
BackgroundMolecular PET imaging: Unlocking the secrets of cancer metabolism
Garg, P., Singhal, G., Horne, D. A., Kulkarni, P., Salgia, R., & Singhal, S. S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117202 · Cited by 23
Metadata
- Authors
- Tricarico, P., Chardin, D., Martin, N., Contu, S., Hugonnet, F., Otto, J., & Humbert, O.
- Affiliations
- Centre Antoine Lacassagne (FR)
- Centre National de la Recherche Scientifique (FR)
- Princess Grace Hospital Centre (MC)
- Corresponding author
- Tricarico, Pierre
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2024-04
- Volume
- 12
- Issue
- 4
- Pages
- e007628
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC11043703
- OpenAlex
- W4395014773
- Semantic Scholar
- 9766d9be31cd4d12c52c055e1cef2684807ade6d
- Cited by
- 38
- References
- 37
- Citations by year
- 2026: 16 · 2025: 19 · 2024: 3
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-27)
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- 3IA cote d'azur (ANR-19-P3IA-0002)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- total metabolic tumor volume, 18F-FDG PET/CT, metastatic non-small cell lung cancer, immune checkpoint inhibitors, immunotherapy response monitoring, prognostic factors, PERCIST criteria, SUVmax, total lesion glycolysis, overall survival, progression-free survival, treatment response prediction, treatment toxicity prediction, treatment de-escalation
- MeSH terms
- Positron Emission Tomography Computed Tomography, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies, Fluorodeoxyglucose F18, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.